Foundation Resource Management Inc. decreased its stake in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 0.3% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 394,929 shares of the biopharmaceutical company's stock after selling 1,337 shares during the period. Pfizer accounts for 3.7% of Foundation Resource Management Inc.'s investment portfolio, making the stock its 9th biggest position. Foundation Resource Management Inc.'s holdings in Pfizer were worth $20,706,000 as of its most recent filing with the SEC.
Several other hedge funds also recently bought and sold shares of PFE. Piscataqua Savings Bank raised its holdings in Pfizer by 0.8% during the second quarter. Piscataqua Savings Bank now owns 25,820 shares of the biopharmaceutical company's stock valued at $1,354,000 after buying an additional 197 shares in the last quarter. Birinyi Associates Inc. raised its holdings in Pfizer by 3.4% during the first quarter. Birinyi Associates Inc. now owns 6,000 shares of the biopharmaceutical company's stock valued at $311,000 after buying an additional 200 shares in the last quarter. Curbstone Financial Management Corp raised its holdings in Pfizer by 0.3% during the first quarter. Curbstone Financial Management Corp now owns 65,901 shares of the biopharmaceutical company's stock valued at $3,412,000 after buying an additional 200 shares in the last quarter. Douglass Winthrop Advisors LLC raised its holdings in Pfizer by 0.3% during the first quarter. Douglass Winthrop Advisors LLC now owns 57,804 shares of the biopharmaceutical company's stock valued at $2,993,000 after buying an additional 200 shares in the last quarter. Finally, LifeSteps Financial Inc. raised its holdings in Pfizer by 2.5% during the second quarter. LifeSteps Financial Inc. now owns 8,179 shares of the biopharmaceutical company's stock valued at $429,000 after buying an additional 201 shares in the last quarter. Hedge funds and other institutional investors own 67.90% of the company's stock.
Get Pfizer alerts:Analysts Set New Price Targets
PFE has been the topic of several recent research reports. SVB Leerink cut their target price on Pfizer from $55.00 to $53.00 and set a "market perform" rating on the stock in a report on Friday, July 29th. Morgan Stanley lowered their price target on Pfizer from $52.00 to $49.00 and set an "equal weight" rating on the stock in a research report on Friday, July 8th. UBS Group set a $59.00 price target on Pfizer in a research report on Thursday, September 1st. The Goldman Sachs Group set a $50.00 price target on Pfizer in a research report on Thursday, September 1st. Finally, Barclays set a $50.00 price target on Pfizer in a research report on Thursday, September 1st. Nine investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $57.00.
Pfizer Stock Down 1.1 %
PFE stock opened at $44.08 on Friday. Pfizer Inc. has a twelve month low of $40.94 and a twelve month high of $61.71. The company has a market cap of $247.39 billion, a PE ratio of 8.63, a price-to-earnings-growth ratio of 0.54 and a beta of 0.70. The business's 50-day simple moving average is $48.24 and its 200 day simple moving average is $50.32. The company has a quick ratio of 1.20, a current ratio of 1.42 and a debt-to-equity ratio of 0.39.Pfizer (NYSE:PFE – Get Rating) last announced its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts' consensus estimates of $1.95 by $0.09. The firm had revenue of $27.74 billion during the quarter, compared to analysts' expectations of $26.20 billion. Pfizer had a net margin of 28.92% and a return on equity of 43.18%. The company's revenue for the quarter was up 46.8% compared to the same quarter last year. During the same quarter last year, the company earned $1.07 earnings per share. On average, research analysts anticipate that Pfizer Inc. will post 6.54 earnings per share for the current year.
Pfizer Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Monday, December 5th. Shareholders of record on Friday, November 4th will be paid a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 3.63%. The ex-dividend date of this dividend is Thursday, November 3rd. Pfizer's dividend payout ratio is 31.31%.
About Pfizer
(Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
Further Reading
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.